BerGenBio

Regulatory Filings • Sep 1, 2020

BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES

BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES

Bergen, Norway, 1 September 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical need, is pleased to announce that a member of the senior

management team will be presenting at the following virtual conferences:

Solebury Trout Zoomside Chat, 1[st]  September 1pm EDT (19:00 CEST)

Live 1-2-1 interview with USA analyst Soumit Roy from Jones Trading.

Registration for

attendees. (https://soleburytrout.zoom.us/webinar/register/WN_tetBZg5dQoiNqYLNM79

8Ag?_x_zm_rtaid=Ib6TkLGxS3yCc47es99Glw.1598899113841.3fa885193236fd1dd4b50f27f830

04ad&_x_zm_rhtaid=17)

LSX Nordic Congress, 1-4 September

Presentation available during the conference

Registration for attendees (https://www.lsxleaders.com/lsx-nordic

-congress/register?utm_term=lsx%20nordic&utm_campaign=LSX+Nordic+2019+

-+Biotech&utm_source=adwords&utm_medium=ppc&hsa_tgt=kwd

-891263778173&hsa_grp=107791471148&hsa_src=g&hsa_net=adwords&hsa_mt=p&hsa_ver=3&h

sa_ad=426680556911&hsa_acc=7380976740&hsa_kw=lsx%20nordic&hsa_cam=9674766415&gcli

d=EAIaIQobChMI1u-jrJ3A6wIVit4YCh2qqQmgEAAYASACEgK1vfD_BwE).

Pareto Securities 11[th] Healthcare Conference, 2-3 September

Presentation on Thursday 3 September, 11:30am CEST

Registration for attendees (https://invitepeople.com/events/13141b0d379bf2).

Wainwright's 22[nd] Annual Global Investment Conference, 14-16 September

Presentation on Wednesday 16 September, 10:30am EST.

Registration for

attendees. (https://www.meetmax.com/sched/event_61861/investor_reg_new.html?atten

dee_role_id=INVESTOR)

All presentations will be made available on the Company website in the

Presentations section on the day of the respective events:

www.bergenbio.com/investors/presentations/

- END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the

biological mechanisms underlying life-threatening diseases. In cancer, AXL

suppresses the body's immune response to tumours and drives cancer treatment

failure across many indications. AXL expression defines a very poor prognosis

subgroup in most cancers. AXL inhibitors, therefore, have potential high value

at the centre of cancer combination therapy, addressing significant unmet

medical needs and multiple high-value market opportunities. Research has also

shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class

selective AXL inhibitor in a broad phase II clinical development programme.

Ongoing clinical trials are investigating bemcentinib in multiple solid and

haematological tumours, in combination with current and emerging therapies

(including immunotherapies, targeted therapies and chemotherapy), and as a

single agent. Bemcentinib targets and binds to the intracellular catalytic

kinase domain of AXL receptor tyrosine kinase and inhibits its activity.

Increase in AXL function has been linked to key mechanisms of drug resistance

and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II oncology clinical development

programme focused on combination and single agent therapy in lung cancer,

leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,

tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is

developing companion diagnostic tests to identify patient populations most

likely to benefit from bemcentinib: this is expected to facilitate more

efficient registration trials supporting a precision medicine-based

commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.